PREAMBLE
The Society of Nuclear Medicine (SNM) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. Its 16,000 members are physicians, technologists, and scientists specializing in the research and practice of nuclear medicine. In addition to publishing journals, newsletters, and books, the SNM also sponsors international meetings and workshops designed to increase the competencies of nuclear medicine practitioners and to promote new advances in the science of nuclear medicine.
The SNM will periodically define new guidelines for nuclear medicine practice to help advance the science of nuclear medicine and to improve the quality of service to patients throughout the United States. Existing Practice Guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated.
Each Practice Guideline, representing a policy statement by the SNM, has undergone a thorough consensus process in which it has been subjected to extensive review, requiring the approval of the Committee on SNM Guidelines, Health Policy and Practice Commission, and SNM Board of Directors. The Practice Guidelines recognize that the safe and effective use of diagnostic nuclear medicine imaging requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published Practice Guideline by those entities not providing these services is not authorized.
These Practice Guidelines are an educational tool designed to assist practitioners in providing appropriate care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. For these reasons and those set forth below, the SNM cautions against the use of these Practice Guidelines in litigation in which the clinical decisions of a practitioner are called into question.
The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the physician or medical physicist in light of all the circumstances presented. Thus, an approach that differs from the Practice Guidelines, standing alone, is not necessarily below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the Practice Guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of the Practice Guidelines.
The practice of medicine involves not only the science, but also the art, of preventing, diagnosing, alleviating, and treating disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to these Practice Guidelines will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of these Practice Guidelines is to assist practitioners in achieving this objective.
I. INTRODUCTION
The intention of this guideline is to assist breast imaging practitioners in selecting patients for, performing, interpreting, and reporting 99m Tc-sestamibi breast-specific g-imaging.
II. GOALS
The goal of breast-specific g-imaging performed with a high-resolution, small-field-of-view, breast-optimized g-camera after intravenous administration of 99m Tc-sestamibi is to detect breast malignancies and is therefore classified under the current procedural terminology codes 78800-78804, Radiopharmaceutical Localization of Tumor or Distribution of Radiopharmaceutical Agent(s).
III. DEFINITIONS
See the SNM Procedure Guideline for General Imaging. diffuse or patchy uptake of mild to moderate intensity, often bilateral, with ill-defined boundaries. 4. Patchy areas of uptake, mild to moderate in intensity (BIRADS 3) are suggestive of benign processes such as mastitis. If bilateral and symmetric, matching the distribution of glandular tissue as seen on the mammogram, patchy areas suggest a glandular response to hormonal influences. 5. Small focal areas of increased uptake in the breast or axilla (in the absence of radiopharmaceutical infiltration) represent an equivocal result, consistent with malignancy, inflammation, atypia, or fat necrosis (BIRADS 4). 6. The intensity of focal uptake in malignant lesions is highly variable. Moderate to intense focal uptake with well-delineated contours is consistent with malignancy (BIRADS 5). 7. Focally increased uptake (1 or more foci) in the ipsilateral axilla, in the presence of a primary lesion, is strongly suggestive of axillary lymph node metastatic involvement (in the absence of radiopharmaceutical infiltration). 8. Masking of high-activity lesions in the breast can improve visualization of adjacent breast tissues. Masking can be performed by placing appropriately sized pieces of lead between the lesion and the detec-tor. Both the masked and the original images should be included in the final display. 9. Sources of error a. Infiltration of the radiopharmaceutical administered in an arm vein may cause false-positive uptake in the axillary lymph nodes. Imaging of the injection site is helpful in evaluating the presence and extent of dose infiltration, particularly if an unsuspected breast lesion is discovered on the same side as the injection. Motion of the breast relative to the detector will decrease the accuracy of the test. b. The sensitivity, specificity, and accuracy of this test depend on several factors, including the size of the breast neoplasm being imaged. Although the sensitivity of this test for subcentimeter tumors is high at around 95%, as with all radiologic examinations sensitivity decreases with lesion size. 
IV. COMMON CLINICAL INDICATIONS

Impression
The report to the referring physician should indicate the most likely diagnosis and should recommend appropriate follow-up as with any breast imaging study, using BIR-ADS classification. 6. Comments, when appropriate
VIII. EQUIPMENT SPECIFICATIONS
A. High-resolution small-field-of-view g-camera B. A symmetric energy window should be centered over the 140-keV photo peak of 99m Tc unless otherwise specified by the manufacturer.
IX. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION CONCERNS
A. Routine quality control procedures should be performed for the scintillation camera as described in the SNM Procedure Guideline for General Imaging. Some of the devices developed for this procedure are based on a pixilated design (both digital and scintillator element types) and not a single crystal design. The quality control and quality assurance of these devices may require additional or modified testing to maintain proper operation. The manufacturer's manuals should be reviewed in addition to these guidelines. B. Quality control measures and radiation safety precautions should be followed as described in the SNM Procedure Guidelines for Use of Radiopharmaceuticals.
X. RADIATION SAFETY IN IMAGING
See Section X of the SNM Procedure Guideline for General Imaging. Dose estimates to adults, children, and the fetus are presented in Tables 1-4 . Regarding dose estimates to breastfeeding patients, ICRP Publication 106 (Appendix D) suggests that no interruption is needed for breastfeeding patients administered 99m Tc-sestamibi or 99m Tc-tetrofosmin (21) . (24) . No information about possible placental crossover of this compound was available for use in estimating fetal doses. (24) . No information about possible placental crossover of this compound was available for use in estimating fetal doses. Separate estimates were not given for rest and exercise subjects.
